文献速递其他结缔组织病

托法替布治疗难治性炎性肌病:41例患者的回顾性队列研究

Tofacitinib therapy in refractory inflammatory myositis: a retrospective cohort study of 41 patients.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

该回顾性队列研究纳入加拿大温哥华单中心2016年6月至2022年12月接受托法替布治疗的41例难治性炎性肌病患者,其中经典型皮肌炎23例、无肌病性皮肌炎12例、多发性肌炎表型6例。托法替布对经典型皮肌炎和无肌病性皮肌炎的皮肤病变有临床和统计学显著改善,但对所有肌炎患者(包括多发性肌炎表型)的肌力未见有意义的应答。53.7%的患者因无获益或死亡停用托法替布。

要点

  • 托法替布对经典型皮肌炎和无肌病性皮肌炎的皮肤病变有临床和统计学显著改善。
  • 所有肌炎患者(包括多发性肌炎表型)中未观察到托法替布对肌力有有意义的应答。
  • 53.7%的患者因无获益或死亡停用托法替布。

核心结论

  • 托法替布似乎对经典型皮肌炎和无肌病性皮肌炎的皮肤表现高度有效,但对皮肌炎或多发性肌炎表型的肌力获益甚微。

研究设计与样本

  • 回顾性队列研究,纳入加拿大不列颠哥伦比亚省温哥华单中心2016年6月至2022年12月接受托法替布治疗的难治性炎性肌病患者,共41例,其中经典型皮肌炎23例、无肌病性皮肌炎12例、多发性肌炎表型6例。

主要发现

  • 经典型皮肌炎和无肌病性皮肌炎组中,托法替布使皮肤病变获得临床和统计学显著改善。
  • 所有肌炎患者(包括多发性肌炎表型)中,未观察到托法替布对肌力有有意义的应答。
  • 53.7%的患者因无获益或死亡停用托法替布。
  • 本研究结束时仍在服用托法替布的19例患者中,托法替布使皮肤疾病活动度获得临床和统计学显著改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the efficacy and safety of tofacitinib in treatment-refractory inflammatory myositis in a real-world clinical setting. METHODS: All patients with refractory inflammatory myositis treated with tofacitinib from a single urban centre in Vancouver, British Columbia, Canada, were included from June 2016 to December 2022. The medical records of these patients were retrospectively reviewed. RESULTS: A total of 41 patients were included, 23 with classic DM, 12 with amyopathic DM (ADM) and six with PM phenotype. The patients failed an average of four to five non-steroidal immunosuppressants before initiation of tofacitinib. In the classic DM and ADM group, tofacitinib offered clinically and statistically significant cutaneous improvement. In all myositis patients including the PM phenotype, no meaningful muscle strength response to tofacitinib was observed. 53.7% of the patients discontinued tofacitinib due to lack of benefit or death. Of the 19 patients who remained on tofacitinib at the conclusion of this study, tofacitinib demonstrated clinically and statistically significant improvement in cutaneous disease activity. CONCLUSION: Tofacitinib appears to be highly effective in targeting cutaneous manifestations in classic DM and ADM; however, minimal benefit in muscle strength in the DM or PM phenotype were observed.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Beckett M, Tan J, Bonnardeaux E, et al. Tofacitinib therapy in refractory inflammatory myositis: a retrospective cohort study of 41 patients. Rheumatology (Oxford). 2024. PMID: 37584672. doi:10.1093/rheumatology/kead404

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。